New York, May 25, 2026, 16:05 (EDT)
- Nasdaq is closed for Memorial Day, leaving Amarin’s last regular close at $14.43 on Friday.
- The stock slipped 0.9% last week, even as the broader U.S. market rose into the long weekend.
- Investors head into the shortened week weighing Amarin’s cash-flow goal against generic-drug and legal risk.
Amarin Corporation plc’s Nasdaq-listed American depositary shares, U.S.-traded certificates for foreign shares, head into a shortened trading week after a muted finish before the Memorial Day break, with investors still looking for proof that cost cuts and partner-led overseas sales can steady the heart-drug maker.
U.S. equity markets, including Nasdaq, are closed Monday for Memorial Day and are due to reopen Tuesday, according to Nasdaq’s 2026 holiday calendar. That leaves Amarin’s Friday close as the latest regular-session price marker.
Amarin ended Friday at $14.43, down 0.82% on the day, with volume of about 35,900 shares. For the week, the stock was down about 0.9% from the previous Friday’s close of $14.56, though it recovered from a Monday close of $14.06.
The move matters now because the tape around Amarin is quiet, not settled. U.S. stocks closed higher Friday and the S&P 500 pulled closer to its record high, while Amarin lagged that broader risk bid.
Biotech was not much help either. The Nasdaq Biotechnology Index closed Friday at 5,891.46, down 0.17%, leaving Amarin trading in a sector that has not fully shared the broader market’s late-May strength.
There was no fresh company catalyst over the long weekend. Amarin’s press-release page listed its latest release as April 29, when the company reported first-quarter results.
That report remains the core background for the stock. Amarin said first-quarter total net revenue rose 7% to $45.1 million, operating loss narrowed to $11.3 million from $16.8 million, and cash and investments increased to $307.8 million at March 31. Chief Executive Aaron Berg called the quarter “early yet measurable progress,” while finance chief Peter Fishman said Amarin produced “positive cash flow” for a second straight quarter. Amarin Corporation plc
The company’s U.S. business still rests heavily on Vascepa, its branded icosapent ethyl drug. Icosapent ethyl is a purified omega-3 fatty acid used to cut certain cardiovascular risks and triglyceride levels. Amarin said U.S. sales were roughly flat from a year earlier, helped by exclusive status with a large pharmacy benefit manager, or PBM, a firm that negotiates drug coverage and pricing for health plans.
Outside the United States, Amarin is leaning on partners. The company said European product revenue rose sequentially under its licensing arrangement with Recordati, which is marketing Vazkepa in parts of Europe. Berg also warned in the same release that European sales could vary quarter to quarter.
The competitive frame is still generic pressure. Hikma Pharmaceuticals is the key named rival in Amarin’s long-running Vascepa fight, and the U.S. Supreme Court heard arguments in April over “skinny labels,” generic-drug labels that omit patented uses. The case could shape how generic firms market drugs when some uses remain under patent. Reuters
The risk is that the shortened week brings little company news and more focus on what Amarin has not yet proven. A weaker legal outcome, softer U.S. prescription trends, or uneven European demand could undercut the cash-flow story. The company has also said the European ramp may not move in a straight line.
For the week ahead, traders will be watching whether Amarin can hold above last week’s low near $14 while broader markets digest post-holiday trading and economic data. For Amarin, the next move likely depends less on one quiet session and more on whether investors believe the leaner model can keep generating cash.
